Invested in rare diseases. Focused on patients

At ITF Pharma UK our sole mission is the treatment of rare diseases. We are invested in delivering better treatments, better outcomes and better quality of life for the thousands of patients suffering with unmet needs. We are committed to supporting patients long term by taking a new approach to developing effective, innovative treatments.

Who are we?

ITF Pharma UK is a specialised pharmaceutical company with an initial focus on pioneering treatments for rare diseases. We are part of the Italian-based ITALFARMACO group and benefit from their global expertise and bespoke in-house research and development to bring innovative solutions to patients with rare diseases.

Our primary focus is Duchenne Muscular Dystrophy (DMD)

DMD is a devastating condition. We are working to provide treatments for the unmet needs of many patients – as well as improving the overall DMD landscape in the UK through education, awareness and innovation.

The UK is supported by years of ITALFARMACO’s global experience

Immuno-oncology

Our immuno-oncologic therapeutic experience is acknowledged by the Italian oncologic community as a reference point in the specialist sector due to the originality of our products and innovative pharmaceutical solutions.

ITALFARMACO’s expertise in developing highly effective preparations in many therapy areas, uniquely positions us to think innovatively and tackle the sophisticated problems rare diseases present.

Gynaecology

Our commitment in this area is aimed at the development of innovative and complete solutions for the different stages of a woman’s life, and covers anaemia, fertility, pregnancy, menopause, gynaecological infection and inflammation.

Cardiovascular and Osteoporosis

We discover, develop, manufacture and market medicines for hypertension and osteoporosis.

Neurology and Psychiatry

We work to provide physicians with solutions for unmet therapeutic needs for diseases of the Central Nervous System.

Thrombosis and Critical Ischemia

Our work in the field of prophylaxis, thrombosis and critical ischemia is strengthened by our long experience with unfractionated heparin. This led to the evolution of a low molecular weight heparin.

ITALFARMACO

Over 90 Countries - 1 Global Vision

High standards, manufacturing expertise and heritage all work together to serve patients who are fighting against a range of rare diseases or diseases that require speciality care.

Founded in 1938, ITALFARMACO is engaged in the discovery, development, manufacturing and marketing of branded prescription and non-prescription medicines. Cutting-edge, high-quality industrial facilities enable research and development expertise to address new, innovative therapeutic treatments for specialty and rare diseases.

Through both marketed medicines and compounds in development, ITALFARMACO is dedicated to serving patients whose needs remain largely unmet.